Wedbush raises Replimune price target to $9, maintains Neutral
Wedbush analyst Robert Driscoll raised Replimune Group's (REPL) price target to $9 from $6, maintaining a Neutral rating. The biotech company reported a fiscal year 2026 net loss of $313.9 million, with R&D and SG&A expenses increasing. The FDA accepted the resubmission of the BLA for RP1, setting a PDUFA goal date of August 2, 2026. The company's cash reserves decreased to $268.9 million as of March 31, 2026.
How this was made
The 30-second read
Why it matters
Price target increase could attract short-term buyers; neutral rating tempers enthusiasm.
Market read
Analyst target adjustment provides a modest trading signal for REPL.
What to watch
Upcoming FDA advisory committee decision could outweigh analyst view.
Background
Wedbush analyst updates valuation for REPL after recent financial and regulatory developments.
Ticker impact
Wedbush raised REPL price target to $9 from $6 while keeping a Neutral rating.
Potential modest price appreciation if market follows target.
Target raise reflects improved valuation but rating unchanged, limiting upside.
Market effects
May influence sentiment in biotech oncolytic therapy sector.
Limited to US biotech investors.
Low global impact.
Counterpoint
Target raise may be premature given ongoing losses and cash burn.
Key entities
- companyReplimune Group
Biotech developing oncolytic immunotherapies.
- analyst_firmWedbush
Equity research firm providing the rating and target.
